Wuhan Hiteck Biological Pharma Co Ltd (300683) — Working Capital to Net Assets Ratio
Wuhan Hiteck Biological Pharma Co Ltd (300683) has a Working Capital to Net Assets ratio of 39.4% as of September 2025. Working capital of CN¥883.24 Million (current assets of CN¥1.13 Billion minus current liabilities of CN¥245.49 Million) is measured against net assets of CN¥2.24 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See Wuhan Hiteck Biological Pharma Co Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Wuhan Hiteck Biological Pharma Co Ltd Working Capital to Net Assets (2013–2024)
This chart shows how Wuhan Hiteck Biological Pharma Co Ltd's Working Capital to Net Assets ratio has evolved across 12 annual periods from 2013 to 2024. As of September 2025, the ratio stands at 39.4%, reflecting working capital of CN¥883.24 Million against net assets of CN¥2.24 Billion CNY. For the complete balance sheet picture, see Wuhan Hiteck Biological Pharma Co Ltd balance sheet assets.
Annual Working Capital to Net Assets for Wuhan Hiteck Biological Pharma Co Ltd (2013–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Wuhan Hiteck Biological Pharma Co Ltd from 2013 to 2024, covering 12 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. Check financial resilience of Wuhan Hiteck Biological Pharma Co Ltd to evaluate the company's liquid asset resilience ratio.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 39.1% | CN¥943.07 Million | CN¥2.41 Billion | CN¥1.31 Billion | CN¥363.26 Million | ▼ -6.7 pp |
| 2023 | 45.8% | CN¥1.14 Billion | CN¥2.50 Billion | CN¥1.49 Billion | CN¥346.15 Million | ▼ -3.9 pp |
| 2022 | 49.6% | CN¥1.16 Billion | CN¥2.34 Billion | CN¥1.44 Billion | CN¥284.73 Million | ▼ -7.3 pp |
| 2021 | 56.9% | CN¥1.33 Billion | CN¥2.34 Billion | CN¥1.58 Billion | CN¥249.25 Million | ▲ +1.2 pp |
| 2020 | 55.7% | CN¥960.99 Million | CN¥1.72 Billion | CN¥1.33 Billion | CN¥367.31 Million | ▼ -5.8 pp |
| 2019 | 61.5% | CN¥1.08 Billion | CN¥1.76 Billion | CN¥1.47 Billion | CN¥385.59 Million | ▼ -3.7 pp |
| 2018 | 65.2% | CN¥1.11 Billion | CN¥1.71 Billion | CN¥1.55 Billion | CN¥431.16 Million | ▼ -25.7 pp |
| 2017 | 90.9% | CN¥1.49 Billion | CN¥1.64 Billion | CN¥1.75 Billion | CN¥255.55 Million | ▲ +9.8 pp |
| 2016 | 81.1% | CN¥570.33 Million | CN¥703.35 Million | CN¥896.10 Million | CN¥325.77 Million | ▼ -0.2 pp |
| 2015 | 81.3% | CN¥485.17 Million | CN¥596.76 Million | CN¥754.66 Million | CN¥269.49 Million | ▼ -3.0 pp |
| 2014 | 84.3% | CN¥452.17 Million | CN¥536.59 Million | CN¥714.05 Million | CN¥261.89 Million | ▲ +13.5 pp |
| 2013 | 70.8% | CN¥180.31 Million | CN¥254.64 Million | CN¥363.87 Million | CN¥183.56 Million | — |